Detail of "287714-41-4"

CAS Number:
287714-41-4
Name:
Rosuvastatin
Molecular Structure:
Formula:
C₂₂H₂₈FN₃O₆S
Molecular Weight:
481.54
Synonyms:
(E)-(3R,5S)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methylsulfonyl)(methyl)amino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoicacid;6-heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (6E)-;
Density:
1.368 g/cm³
Boiling Point:
745.6 °C at 760 mmHg
Flash Point:
404.7 °C

Supplier Location
Supplier Location
- China (Mainland)(13)
- India(7)
- United States(1)
Business Type
Business Type
- Lab/Research institutions(2)
- Manufacturers(1)
- Trading Company(12)
Certificates
Certificates
- Production License(1)
- QS(1)
- ISO (0)
Exhibitions
Exhibitions
- CPhI China
- API China

Display：

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

HMG-CoA reductase inhibitor-containing implantable medical devices: HMG-CoA reductase inhibitor-containing implantable medical devices. Sugimoto, Ryota (Terumo Corp., Japan). Jpn. Kokai Tokkyo Koho JP 2004041331 A2 12 Feb 2004, 10 pp. (Japanese). (Japan). CODEN: JKXXAF. CLASS: ICM: A61L027-00.In this article, certain chemicals are used. Some of their cas registry numbers are 134523-00-5 and 287714-41-4 ICS: A61M029-02. APPLICATION: JP 2002-200712 10 Jul 2002. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Title devices, which are left in the lumen, e.g. blood vessel, airway, urinary tract, etc., for prevention of restenosis, release HMG-CoA reductase inhibitor at 1 ′ 10-9 to 1 ′ 10-4 M. Thus, a stent was coated with simvastatin, overcoated with silicone, and implanted in artery in rabbits. The concn. of simvastatin in the tissue was 9.3 ′ 10-6 M. .

Future prospects of new statins: Future prospects of new statins. Bujo, Hideaki (Graduate School of Medicine, Chiba University, Japan). Chiryogaku, 36(5), 502-505 (Japanese) 2002 Raifu Saiensu Shuppan K.K. CODEN: CHRYDT. ISSN: 0386-8109. 147511-69-1 and 287714-41-4 are also in the experiment. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Future prospects of new hypolipemic agents statins such as pravastatin, pitavastatin, and rosuvastatin etc. as NADPH-hydroxymethylglutaryl-CoA reductase inhibitors are reviewed. .